Connect with us

Politics

DEA’s Approach To Marijuana Rescheduling Is Creating Deep Uncertainty For Regulators, Patients And Market Operators (Op-Ed)

Published

on

“Supply chains in many states will not have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market.”

By Gillian L. Schauer, Cannabis Regulators Association

Late last month, the Drug Enforcement Administration (DEA) took three significant actions related to federal medical marijuana rescheduling: issuing guidance to DEA applicants, issuing orders to show cause concerning DEA registration and granting the first Schedule III medical marijuana registrations.

These actions have created deep uncertainty and disruption for regulators, patients and market operators. They came with little or no advance notice to state regulators and minimal communication afterward.

Timely Applicant Guidance

Most of the chaos in states stems from an agency-issued letter to timely applicants advising businesses that had applied for DEA registration that they can engage in Schedule III medical marijuana activities with other timely applicants and with registrants—but that they “may not lawfully engage in any schedule III medical marijuana activities with entities that did not complete an application for DEA registration between April 28, 2026 and June 26, 2026 or that have not applied for a DEA schedule III medical marijuana registration, until those entities become DEA registrants.”

The letter states that if a timely applicant engages in schedule III medical marijuana activities (e.g., commerce) with someone other than a timely applicant or DEA registrant, it could be grounds for denial of their application or registration. The letter gives timely applicants until November 29 to establish compliant supply chains.

This information has, virtually overnight, bifurcated most state medical marijuana marketplaces into two markets: one of DEA registrants and timely applicants, and one of state licensees who are neither DEA applicants nor registrants.

Given that every state directly or indirectly outlaws interstate commerce (it is considered diversion across most states and is grounds for immediate suspension of a license) supply chains in many states will not have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market.

Regulators and market operators across multiple states are currently trying to assess supply chain viability under this new market bifurcation. The DEA provided a list of timely applicants, but only listed de-identified DEA numbers. Regulators have been largely unable to obtain a list from DEA of the businesses in their states who are timely applicants or DEA registered and have been left to try to piece it together on their own by requesting DEA numbers from licensees.

Bifurcated markets will create supply chains that are not viable, and in some cases, may create monopolies within a market.

For example, one state identified that nearly three-quarters of their state-licensed dispensaries are timely applicants, leaving a small number of dispensaries in the non-DEA state-only market. Another state identified that while most state-licensed dispensaries are timely applicants, only few cultivators are, making it likely that the DEA market in that state would necessitate interstate commerce for a complete supply chain, which is illegal in that state. Another state identified that all the third-party testing labs in the state applied to be DEA registered, leaving no testing labs in the state-only market.

With bifurcated and incomplete supply chains in states, some businesses will not survive in either market, patient access will be impacted, diversion and inversion will become more difficult for regulators to detect, health and safety compliance will be eroded and state revenues that support a variety of public services will decrease.

Orders To Show Cause Raise Questions About DEA Registration Eligibility Across Entire States

While the bifurcated DEA and non-DEA marketplace seems to be the reality for most states, DEA applicants across at least seven states or jurisdictions have received a DEA order to show cause (OSC), stating that state policies will prevent the applicant from DEA registration.

DEA has flagged four main state policies in these orders: (1) dual purpose marijuana licensing approaches that permit a licensee to participate in both the medical and non-medical marketplace in the state, (2) self-certification programs wherein a patient (e.g., a veteran or patient on hospice) is able to self-certify that they have a qualifying condition for medical marijuana use in the state, (3) programs that allow dispensing without a certification or prescription and (4) synthetic cannabinoids dispensed within the medical marijuana supply chain.

At this point, OSCs have typically been delivered to only a small number of applicants in each of the seven states or jurisdictions, but the orders all state that based on the identified deficiencies in state policy, DEA cannot permit any applicant operating under the state’s regime to participate in the federal registration system.

Presumably, that means that all applicants in the state can expect to receive an OSC. However, applicants are receiving OSCs in an inconsistent manner, including in terms of parity within and between states, timing of OSC delivery and delivery method (e.g., via mail, in person or through a delivery service).

Without communication from DEA, state regulators have been left to guess about whether all or only some applicants in the state will receive these orders.

In addition, questions remain about the criteria DEA is using to issue OSCs, particularly when it comes to dual-purpose marijuana licensing programs. While several states have very similar regulations for dual-purpose licensing, only a few of those states have applicants who have received letters disqualifying their registration based on state policies.

In a number of states with similar potentially disqualifying policies, applicants have received the timely applicant letter. Marketplaces are already shifting across a number of states as applicants try to come into compliance with the timely applicant letter, even though some of those states may soon be added to the OSC list and deemed ineligible.

Impacts On Patients

Several aspects of these DEA actions stand to impact patients directly.

First, a main focus of the DEA’s OSCs was on self-certification programs, which typically exist in states to serve patients receiving hospice care, or veterans who get their care from the U.S. Department of Veterans Affairs, where clinicians are not permitted to write a recommendation or certification for medical cannabis. These programs typically represent a small proportion of state certifications and provide access to patients who cannot easily obtain a clinician’s written recommendation.

Memorandums of agreement (MOAs) that timely applicants have to sign before receiving DEA registration include a section stating that dispensers agree they will not dispense marijuana to any qualifying out-of-state patient or caregiver. This means the DEA system will not allow medical reciprocity, which will make it difficult for patients to get medical marijuana when they travel to another state.

Finally, the bifurcated DEA and non-DEA supply chain could have real impacts on patient acess in states. For example, if a patient lives in a rural area with access to only one dispensary, and the dispensary applied for DEA registration but the manufacturer who makes the medical marijuana products the patient uses did not apply for DEA registration, then that patient could lose access to those products. Or if the supply chain is incomplete, operators in either the DEA supply chain or the state-licensed non-DEA market may go out of business altogether.

The Cannabis Regulators Association (CANNRA) has continued to raise these issues to the DEA without substantive engagement. Meanwhile, regulators are trying to figure out how to continue to serve patients and regulate viable and compliant state markets without sufficient information about what DEA’s plans are now or into the future.

Gillian Schauer is executive director of the Cannabis Regulators Association (CANNRA), a nonpartisan, nonprofit association of government agencies regulating cannabis, marijuana and/or hemp across more than 45 states, D.C. and three U.S. territories.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Become a patron at Patreon!
Advertisement

Marijuana News In Your Inbox

Get our daily newsletter.

Support Marijuana Moment

Add Marijuana Moment as a preferred source on Google.

Marijuana News In Your Inbox

 

Get our daily newsletter.